Aims: To investigate the effects of semaglutide vs placebo on glucagon and other counterregulatory hormones during hypoglycaemia in type 2 diabetes (T2D).
, glycated haemoglobin 60.8 (44.3-83.6) mmol/mol (7.7 [6.2-9.8]%), and diabetes duration 4.5 (0.3-13.2) years. A total of 35 participants completed the trial and were included in the analyses. During the hypoglycaemic clamp from 5.5 mmol/L PG to nadir, the absolute change in mean glucagon concentration was similar for semaglutide vs placebo: 88.3 vs 83.1 pg/mL (estimated difference 5.2 pg/mL [95% confidence interval −7.7 to 18.1]). Concentrations of other counterregulatory hormones increased with both treatments, with a statistically significantly lower increase for noradrenaline and cortisol with semaglutide vs placebo. The glucose infusion rate to maintain constant clamp levels was similar for each treatment group, suggesting an overall similar counterregulatory response. The mean hypoglycaemic symptom score and proportion of participants recognizing hypoglycaemia during the study were lower for semaglutide vs placebo treatment at nadir, but cognitive function test results were similar. No new safety issues were observed for semaglutide.
Conclusions: Semaglutide treatment did not compromise the counterregulatory glucagon response during experimental hypoglycaemia in people with T2D.
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| INTRODUCTION
Type 2 diabetes (T2D) is a complex metabolic disorder involving increased insulin resistance, coupled with progressive loss of β-cell mass and function, and leading to dysregulation of insulin and glucagon secretion.
1,2 While many treatment options for T2D are available, one limitation is the risk of hypoglycaemia. 3 Glucagon is a key hormone in the regulation of glucose homeostasis. 4, 5 The counterregulation of hypoglycaemia depends largely on increases in glucagon and adrenaline secretion and decreased insulin secretion. 6 In people with insulin-deficient diabetes, the key counterregulatory responses of increased glucagon and suppressed insulin are impaired and the sympathoadrenal response, mainly adrenaline, becomes important. 7, 8 Counterregulatory hormone deficiencies tend to be mild in the early stages of the T2D, 9 developing only as the disease advances and endogenous insulin secretion declines. 10 Glucagon-like peptide-1 (GLP-1), an incretin hormone secreted by intestinal L cells in response to food intake, [11] [12] [13] inhibits glucagon secretion and stimulates insulin secretion in a glucose-dependent manner. 12, 13 Semaglutide (Novo Nordisk, Bagsvaerd, Denmark), a GLP-1 analogue, is approved in major markets for the treatment of T2D. With 94% homology to native GLP-1, semaglutide has three structural modifications that prolong its half-life to~1 week, making it appropriate for once-weekly administration. 3, 12 In phase III trials, semaglutide led to improved glycaemic control and decreased body weight, with a safety profile similar to other GLP-1 receptor agonists (GLP-1RAs). [14] [15] [16] Liraglutide, having a similar structure to semaglutide but a different pharmacokinetic profile, was found to have no effect on the counterregulatory responses to hypoglycaemia. [17] [18] [19] These responses have not been evaluated in people treated with semaglutide. Because of the ability of semaglutide to suppress glucagon, it is important to establish that the glucagon counterregulatory response during hypoglycaemia is preserved.
The primary objective of the present study, therefore, was to investigate the effect of semaglutide vs placebo on the glucagon response during hypoglycaemia in people with T2D, and effects on other counterregulatory hormones (adrenaline, noradrenaline, cortisol and growth hormone), hypoglycaemic symptoms, cognitive function and vital signs. 
| PARTICIPANTS AND METHODS

| Trial design
Eligible participants were randomized 1:1 to one of two treatment sequences: semaglutide 1.0 mg/placebo or placebo/semaglutide 1.0 mg ( Figure 1A ). Participants were assigned by the investigators at the trial site to the lowest available randomization number on a participant-specific pre-packed trial product (Novo Nordisk). The sponsor, trial participants and investigators remained blinded to treatment allocation during the trial. Once-weekly treatment with the pre-packed trial product was self-administered subcutaneously using PDS290 peninjectors (Novo Nordisk). As per usual practice, the semaglutide dose was escalated, starting at a dose of 0.25 mg for 4 weeks, with subsequent dose escalation to 0.5 mg for 4 weeks, followed by the maintenance 1.0-mg dose for 5 weeks. Throughout the trial, dosing was to occur on the same week day at any time of day. The participants' background metformin treatment remained unchanged. Each group underwent two treatment periods, each followed by a hypoglycaemic clamp procedure and 5 weeks of pharmacokinetic blood sampling, separated by a 1-to 3-week washout period, with a follow-up visit in the final week of the second sampling period ( Figure 1A ).
| Hypoglycaemic clamp
Approximately 48 hours after the last (13th) treatment dose, coinciding with the expected maximum concentration of semaglutide, Other secondary endpoints assessed during the clamp at each target PG level included symptoms of hypoglycaemia, measured using 
| Endpoints and assessments during the treatment period
Effects of semaglutide vs placebo on glucose metabolism in each of the 2 treatment periods were assessed by evaluating the concentration and change from baseline to end-of-treatment (1 week after the 13th dose) in HbA1c, fasting serum glucose and fasting Cpeptide. Because of the crossover design, baseline assessments were made before the first and second treatment periods.
Pharmacokinetic endpoints are described in the Supplemental
Methods (File S1).
| Safety assessments
The safety evaluation included assessments from baseline to followup in the number of treatment-emergent adverse events, defined as starting on or after the first treatment day and no later than the follow-up visit. Self-reported hypoglycaemic episodes, classified according to American Diabetes Association criteria, 3 were also assessed. Nocturnal episodes had time of onset between 12:01 AM and 5:59 AM. Additional safety endpoints included haematology, biochemistry, amylase and lipase, calcitonin, urine analysis, vital signs, physical examination and ECG, body weight, and the development of anti-semaglutide antibodies.
| Laboratory assays
Plasma glucagon concentrations were analysed using an enzymelinked immunosorbent assay (Mercodia AB, Uppsala, Sweden). 28 Measurements of other variables were made using standard methods, as described in the Supplemental Methods (File S1). 
| Statistical methods
A sample size of 30 completing participants was determined based on the criterion that the width of the 95% confidence interval (CI) for the treatment comparison of the primary endpoint was within AE23.3 pg/mL with 80% probability. This was based on a withinparticipant SD of 40 pg/mL from a previous trial. 17 Assuming a 20% dropout rate, at least 38 randomized participants were required to obtain 30 trial-completing participants.
The pre-specified analyses used data from the full analysis set of all randomized and exposed participants with at least one postbaseline assessment. The safety analysis set included all exposed participants. The primary endpoint, absolute change in glucagon concentration from target level 5.5 mmol/L to nadir, was analysed using an analysis of covariance model, with treatment, period and participant as fixed effects. As an additional analysis of the primary endpoint, the relative change was calculated and analysed based on log- The baseline characteristics of the 37 participants who comprised the full analysis set are shown in Table 1 .
| Results of the hypoglycaemic clamp
As expected, similar mean PG levels in the semaglutide and placebo groups were achieved at the 5.5-and 3.5-mmol/L target PG levels. Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin. Data are presented as means (SD), unless otherwise stated, and were assessed at screening, except for body weight and diabetes-related characteristics, which were assessed at baseline. All 37 participants were white and not Hispanic or Latino.
placebo, except that the relative change from fasting to nadir was greater with semaglutide (estimated treatment ratio 1.23 [95% CI
1.01-1.49]).
The mean concentrations of other counterregulatory hormones increased in both treatment groups in response to hypoglycaemia from 5.5 mmol/L glucose to nadir ( Figure 2B -E), with lower increases in the absolute concentrations of noradrenaline and cortisol with semaglutide vs placebo ( Table 2 ).
Mean C-peptide concentrations decreased with both treatments in response to hypoglycaemia, although semaglutide vs placebo treatment resulted in significantly greater mean C-peptide concentrations at each target PG level ( Figure 2F ). The estimated absolute decrease in mean C-peptide from 5.5 mmol/L to nadir was greater for participants in the semaglutide group than the placebo group (Table 2) .
| Time to reach recovery
The proportion of participants who recovered spontaneously (reaching PG ≥4.0 mmol/L < 40 minutes after termination of the insulin infusion at nadir) was~50% in each group. Recovery was achieved within a similar time for participants when treated with semaglutide (geometric mean 44 minutes) and placebo (mean 47 minutes). 
| Glucose infusion rate
The AUC GIR was similar in the semaglutide and placebo treatment groups throughout the clamp ( Figure S1 in File S1).
| Hypoglycaemia symptoms and recognition and cognitive function tests
No difference between treatments was observed in the estimated mean hypoglycaemic symptom score at the target PG level of 5.5 mmol/L, whereas at 3.5 mmol/L and nadir, the mean hypoglycaemic symptom score was 11% to 12% lower with semaglutide vs placebo (P = 0.002 and 0.019, respectively; Figure 3 ).
Regarding hypoglycaemia recognition, all participants answered The results of three cognitive function tests indicated no effect of semaglutide on cognitive function, with similar results across all PG levels in the semaglutide and placebo groups ( Figure S2 in File S1).
| Vital signs
During the clamp, there were no systematic differences between semaglutide and placebo in the response to hypoglycaemia for heart rate, systolic or diastolic BP, with no statistically significant treatment differences with respect to mean changes from target PG level 5.5 mmol/L to nadir and 5.5 to 3.5 mmol/L (Table S2 in File S1).
| Pharmacodynamic changes during treatment
One week after the last (13th) treatment dose, the mean (SD) decreases from baseline for semaglutide in HbA1c, fasting serum glucose and body weight were greater than those observed with pla- Table S3 in File S1). The mean fasting C-peptide levels increased by 27% from baseline to end-oftreatment with semaglutide vs placebo).
| Semaglutide pharmacokinetics
Semaglutide pharmacokinetic variables were similar to those observed in previous trials, 13 
| Safety
The number of adverse events and the proportion of participants reporting events, which were all of mild or moderate severity, were greater for semaglutide vs placebo (Table S4 in File S1). The most common adverse events were gastrointestinal disorders and infections and infestations. Seven serious adverse events were reported by 5 participants (see the Supplemental Results for details in File S1).
No deaths or pancreatitis cases were reported during the trial. Excluding episodes induced during the clamp, 4 participants on placebo treatment reported 6 hypoglycaemic episodes; one was severe or blood-glucose confirmed symptomatic 3 (Table S4 in File S1), and no nocturnal episodes occurred. b Relative change for glucagon was an additional analysis of the primary endpoint. Relative changes in other variables than glucagon are included in Table S1 in File S1. In general, the physiological response to hypoglycaemia depends on the primary corrective actions of decreased insulin and increased glucagon concentrations. 6 Semaglutide, similarly to other GLP-1 analogues, inhibits glucagon secretion at fasting glucose concentrations, 12, 13, 29 as observed in the present trial, which helps to improve glycaemic control. 30 It is, nevertheless, important that the glucagon inhibition does not impair the counterregulatory response under hypoglycaemic conditions. The effect of GLP-1 and GLP-1RAs on the counterregulatory response to hypoglycaemia has been investigated in several studies because impaired counterregulation could potentially limit the use of treatment. Native GLP-1 had no effect on the response to hypoglycaemia in healthy volunteers, 31 neither did other GLP-1RAs in people with type 1 diabetes or T2D. [17] [18] [19] 32, 33 The present trial included participants with T2D treated only with metformin, to ensure an adequate glucagon response during the clamp; inclusion of participants with more progressed disease would have lessened the likelihood of detecting an effect of semaglutide. The fact that participants exhibited a robust glucagon response might also explain why not all attained the nadir target of 2.5 mmol/L PG level, despite the constant insulin delivery.
More than half of those participants who did not achieve the nadir target failed to do so with both treatments.
Absolute concentrations of other counterregulatory hormones exhibited a smaller increase with semaglutide than with placebo, statistically significantly so for noradrenaline and cortisol; however, the observed differences were unlikely to be of clinical relevance and may have been influenced by improvements in glycaemic control with semaglutide. Adrenaline, as a third defence against hypoglycaemia, normally becomes important only when glucagon is deficient; noradrenaline, cortisol and growth hormone play even smaller roles. 8 The higher absolute concentrations of C-peptide, a marker of endogenous insulin production, observed with semaglutide vs placebo at each target PG level during the clamp were consistent with the ability of GLP-1RAs to stimulate insulin secretion in a glucose-dependent manner. 12, 13, 29 Importantly, C-peptide levels decreased with progressing hypoglycaemia; the decrease being more pronounced for partici- Nevertheless, these observations raise the possibility that semaglutide might reduce hypoglycaemia awareness and so lead to an increased risk of severe hypoglycaemia in clinical practice. Reassuringly, the glucagon response during hypoglycaemia, the primary counterregulatory hormone, was unaffected in the presence of semaglutide. Indeed, the relative glucagon response was greater than that observed with placebo and, conceivably, a reduced sympathoadrenal response may reflect more efficient counterregulation during hypoglycaemia. This interpretation is supported by similar GIRs in the two arms and the similar rates of glucose recovery. Furthermore, in the studies of semaglutide conducted to date, no increases in rates of hypoglycaemia have been noted, although these (and indeed the present study) were not powered to evaluate differences in severe hypoglycaemia; [14] [15] [16] 34 however, in the LEADER trial with the closely-related molecule, liraglutide, a statistically significantly lower incidence of severe hypoglycaemia was seen for liraglutide compared with placebo. 35 In summary, the clinical relevance of the observations in the present trial remains uncertain.
Providing a definite answer would require a specifically designed, adequately powered trial.
As expected, semaglutide treatment led to reductions in HbA1c, fasting serum glucose and body weight, and increases in fasting Cpeptide, consistent with findings from larger phase III trials, [14] [15] [16] 34 and concomitant with lower glucagon concentrations with semaglutide vs placebo at fasting glucose levels before the clamp. Collectively, data suggest that semaglutide provides effective glycaemic control with a low risk of hypoglycaemia, [14] [15] [16] 34 consistent with its mode of action. 12, 13 Semaglutide was generally well tolerated and reported side effects were consistent with other semaglutide trials. [14] [15] [16] 34 No unexpected treatment-related safety issues were identified. The increased heart rate with semaglutide is a known effect of treatment with GLP1RAs, 36 although a large cardiovascular outcomes trial showed a significant reduced risk of cardiovascular events with semaglutide. 
